English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background  The role of single nucleotide polymorphisms (SNPs) associated with inflammatory bowel disease (IBD) is gaining interest. With the advent of novel therapies, personalized treatment in IBD is a future goal. We wondered whether IBD-associated SNPs are able to predict response to anti-TNFα treatment.    Methods  Data on treatment use and primary response, loss of response and side effects to anti-TNFα treatments were retrieved for 570 IBD patients. rs13361189 ( IRGM ), rs10210302 ( ATG16L1 ), rs2066844, rs2066845, rs2066847 ( NOD2 ), rs35873774 (XBP1), rs11175593 ( LRRK2 ), rs11465804 ( IL23R ), rs2301436 ( CCR6 ), rs744166 ( STAT3 ) and rs4821544 ( NCF4 ) SNP status were determined.    Results  No associations were found between genetic variants of the  LRRK2 ,  CCR6 ,  IL23R  and  NCF4  genes and response to anti-TNFα. For  NOD2  and  XBP1  associations were found, however, these associations were not strong enough to survive multiple testing corrections. Strikingly, patients carrying the  ATG16L1  T300A variant were more likely to be treated with adalimumab, even after correction for disease phenotype, disease behavior and age (p = 0.004, OR 2.8, CI 1.6–5.0).    Conclusions  Genetic polymorphisms in the known IBD-associated gene  ATG16L1  correlate with requirement of treatment, suggesting a different IBD disease phenotype in these patients. Further investigation will need to elucidate the implications of these findings and identify the underlying disease characteristics.    Electronic supplementary material  The online version of this article (10.1186/s12967-017-1355-9) contains supplementary material, which is available to authorized users.

Genetic polymorphism in ATG16L1 gene is associated with adalimumab use in inflammatory bowel disease